Companies › Inozyme Pharma
1 active drug program in 3 registered trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Metabolic and endocrine.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| INZ-701 Recombinant ENPP1-Fc fusion protein | ENPP1 | Phase 3 | Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency; Gene Mutations; Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06046820 | INZ-701 | Phase 3 | Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency | Metabolic and endocrine | Jan 2026 |
| NCT05734196 | INZ-701 | Phase 1 | Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency | Metabolic and endocrine | Sep 2026 |
| NCT06462547 | INZ-701 | Phase 2 | Gene Mutations | Metabolic and endocrine | Sep 2026 |
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Orphalan Lumos Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.